149 related articles for article (PubMed ID: 28922591)
1. Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial.
Xiao L; Ganocy SJ; Findling RL; Chang K; DelBello MP; Kane JM; Tohen M; Xiang YT; Correll CU
J Clin Psychiatry; 2017; 78(9):e1158-e1166. PubMed ID: 28922591
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
4. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.
Suppes T; Brown E; Schuh LM; Baker RW; Tohen M
J Affect Disord; 2005 Dec; 89(1-3):69-77. PubMed ID: 16253344
[TBL] [Abstract][Full Text] [Related]
5. Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program.
Szegedi A; Zhao J; McIntyre RS
J Affect Disord; 2013 Sep; 150(3):745-52. PubMed ID: 23473546
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.
Kemp DE; Johnson E; Wang WV; Tohen M; Calabrese JR
J Clin Psychiatry; 2011 Sep; 72(9):1236-41. PubMed ID: 21457677
[TBL] [Abstract][Full Text] [Related]
7. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
Findling RL; Nyilas M; Forbes RA; McQuade RD; Jin N; Iwamoto T; Ivanova S; Carson WH; Chang K
J Clin Psychiatry; 2009 Oct; 70(10):1441-51. PubMed ID: 19906348
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
Perlis RH; Baker RW; Zarate CA; Brown EB; Schuh LM; Jamal HH; Tohen M
J Clin Psychiatry; 2006 Nov; 67(11):1747-53. PubMed ID: 17196055
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S
J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327
[TBL] [Abstract][Full Text] [Related]
10. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF
J Clin Psychiatry; 2001 Apr; 62(4):273-81. PubMed ID: 11379842
[TBL] [Abstract][Full Text] [Related]
11. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.
Azorin JM; Sapin C; Weiller E
J Affect Disord; 2013 Feb; 145(1):62-9. PubMed ID: 22868059
[TBL] [Abstract][Full Text] [Related]
12. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
13. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.
Stentebjerg-Olesen M; Ganocy SJ; Findling RL; Chang K; DelBello MP; Kane JM; Tohen M; Jeppesen P; Correll CU
Eur Child Adolesc Psychiatry; 2015 Dec; 24(12):1485-96. PubMed ID: 26032132
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.
Katagiri H; Tohen M; McDonnell DP; Fujikoshi S; Case M; Kanba S; Takahashi M; Gomez JC
BMC Psychiatry; 2013 May; 13():138. PubMed ID: 23672672
[TBL] [Abstract][Full Text] [Related]
15. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5.
Tohen M; McIntyre RS; Kanba S; Fujikoshi S; Katagiri H
J Affect Disord; 2014 Oct; 168():136-41. PubMed ID: 25046739
[TBL] [Abstract][Full Text] [Related]
17. Early Nonresponse in the Antipsychotic Treatment of Acute Mania: A Criterion for Reconsidering Treatment? Results From an Individual Patient Data Meta-Analysis.
Welten CC; Koeter MW; Wohlfarth TD; Storosum JG; van den Brink W; Gispen-de Wied CC; Leufkens HG; Denys DA
J Clin Psychiatry; 2016 Sep; 77(9):e1117-e1123. PubMed ID: 27780320
[TBL] [Abstract][Full Text] [Related]
18. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118
[TBL] [Abstract][Full Text] [Related]
20. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.
Sachs GS; Greenberg WM; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
J Affect Disord; 2015 Mar; 174():296-302. PubMed ID: 25532076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
